Avecho Biotechnology (ASX:AVE) said that three newly activated sites in Sydney and the Gold Coast have started screening and recruitment for its phase three clinical trial investigating its oral cannabidiol capsule for the treatment of insomnia, according to a Tuesday filing with the Australian bourse.

The sites provide access to independent databases of insomnia patients, the filing said.

The trial will dose about 210 participants before the end of the year, with results expected in early 2026, the filing added.

Shares of the company rose 11% at market close.